Printer Friendly


 SAN DIEGO, Nov. 23 /PRNewswire/ --- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) today announced that at its request the United States Patent and Trademark Office ("USPTO") has declared an interference between a U.S. patent application, of which Telios is the exclusive licensee, and a U.S. patent assigned to Merck & Co. Inc. Also included by the USPTO in the interference is a patent application submitted by researchers affiliated with SmithKline Beecham and another patent application submitted by researchers affiliated with Asahi Glass Co.
 All of the parties are claiming inventions related to cyclic peptides containing the amino acid sequence arginine-glycine- aspartic acid (RGD) and its derivatives. Such peptides may be useful in the treatment of diseases, such as heart attacks, strokes, osteoporosis and cancer, resulting from unwanted interactions between cells and the extracellular matrix. Telios has a worldwide exclusive license to patents issued to La Jolla Cancer Research Foundation covering the composition of matter for peptides containing RGD and their use in therapeutic applications including the prevention of platelet aggregation.
 Cell surface receptors known as integrins attach to specific matrix proteins based upon their respective three dimensional structures. By taking advantage of these structural differences, Telios is developing RGD-containing pharmaceuticals, such as its platelet aggregation inhibitor, TP-9201, for which an investigational new drug (IND) application was filed this month with the U.S. Food and Drug Administration in order to commence human clinical trials early next year.
 An interference is declared when the USPTO is of the opinion that the subject matter claimed is patentable and the same invention is claimed by multiple parties in pending patent applications and/or unexpired U.S. patents. The purpose of an interference proceeding is to determine which party was the first to invent the claimed invention, and therefore entitled to the exclusive patent rights.
 The party whose patent application has the earliest filing date is designated the "Senior Party" in the interference, with the parties having later filing dates being designated the "Junior Parties." The USPTO has designated the La Jolla Cancer Research Foundation, from which Telios licensed the subject invention, to be the Senior Party in the pending interference.
 Telios expects that it may take as long as several years before the USPTO decides the matter. The prosecution of all patent applications involved in the interference is stayed until resolution of the interference. The progress of the interference proceeding will remain confidential until a final resolution is reached and patent applications result in issued patents or are abandoned.
 Telios is a leader in the development of "matrix medicine" -- a new class of therapeutic products that modify or mimic extracellular matrix functions in tissue repair and disease. Telios is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases (such as certain kidney, liver and lung diseases), cardiovascular diseases, and osteoporosis. In March 1993, Telios submitted a Pre-Market Approval application (PMA) to the U.S. FDA for the use of ARGIDENE(TM) Gel in the treatment of diabetic foot ulcers.
 -0- 11/23/93
 /CONTACT: Audrey D. Keane, director of Corporate Development of Telios Pharmaceuticals, 619-622-2615/

CO: Telios Pharmaceuticals Inc.; Merck & Co. Inc.; SmithKline Beecham
 Asahi Glass Co. ST: California IN: MTC SU:

LM-MF -- SD003 -- 7454 11/23/93 18:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 23, 1993

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters